Study on Mezigdomide, Carfilzomib, and Dexamethasone for Treating Relapsed or Resistant Multiple Myeloma with Tumors Outside the Bone Marrow

Inclusion Criteria

• Must be 18 years or older.
• Have a performance status score of 0 to 2, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have relapsed or resistant multiple myeloma with at least one tumor outside the bone marrow that can be biopsied.
• Have measurable disease based on specific medical tests.
• Have adequate blood cell counts and organ function, including:
  • Neutrophil count of at least 1 x 10^9/L.
  • Platelet count of at least 75 x 10^9/L.
  • Total bilirubin level within 1.5 times the normal limit.
  • Liver enzymes within 3 times the normal limit.
  • Kidney function with creatinine clearance of at least 30 mL/min.
  • Heart function with a pumping ability of at least 40%.
• Women of childbearing potential must use effective birth control during the study and for a specified time after treatment.
• Men must use contraception during the study and for a specified time after treatment.
• Must understand the study and sign a consent form before participating.

Exclusion Criteria

• Have a history of severe allergic reactions to any of the study drugs or similar medications.
• Are taking certain medications that affect the liver or stomach within two weeks before starting the study.
• Cannot or will not take blood clot prevention medication as required by the study.
• Have active bleeding or are resistant to platelet transfusions.
• Have medical conditions that pose a high risk or affect participation in the study.
• Have an active infection requiring treatment within the past 14 days.
• Have had another cancer, except for certain non-invasive cancers, unless free of disease for at least 3 years.
• Are receiving other treatments for multiple myeloma, except for certain medications for symptom management.
• Are pregnant or breastfeeding.
• Have serious mental health issues, alcoholism, or drug addiction that may interfere with the study.
• Have active HIV or hepatitis B or C infections.
• Have certain rare conditions like systemic amyloidosis or POEMS syndrome.
• Have had a stem cell transplant within 12 weeks before the study.
• Have had radiation therapy within 14 days before starting the study, unless it covered a small area.
• Cannot tolerate steroid therapy.
• Have uncontrolled illnesses like heart failure or severe heart problems.
• Are resistant to Carfilzomib in the most recent treatment.
• Have been treated with Mezigdomide before.
• Cannot undergo conscious sedation.
• Are unwilling or unable to follow the study requirements.
• Have any condition that makes participation in the study unsuitable.